Introduction
GH is a potent anabolic hormone and most of its biological action is mediated by insulin-like growth factor (IGF)-I. The GH-IGF-I axis is physiologically controlled by the hypothalamic releasing and inhibitory hormones, GH-releasing hormone (GRH) and somatostatin (SRIF) [1, 2] . Hypothalamic GRH stimulates both secretion and gene expression of GH through G protein-coupled receptors, GRH receptors, causing activation of cyclic AMP and Akinase systems in the somatotropes [1, 2] . Many humoral factors affect GH secretion and some of their effects might be caused by changes in GRH and its receptor status.
Blood glucose levels are known to alter GH secretion [3] [4] [5] [6] [7] [8] [9] [10] . GH responses to hyperglycemia are similar among species, while GH responses to hypoglycemia differ between some species [3] [4] [5] [6] [7] [8] [9] [10] .
In rats, both hyper-and hypoglycemia inhibit pulsatile GH secretion [6, 7] . Evidence suggests that glucosensitive neurons, "glucoreceptors"
, are present in the lateral hypothalamic area of the hypothalamus in primates [4] and rats [11, 12] of in vivo systems seems preferable. In this review, the changes in hypothalamic GRH and SRIF mRNA levels are described when hyperor hypoglycemia is induced in conscious rats. Further, the effects of chronic hyperglycemia on these mRNA levels in streptozotocin-induced diabetic mice are reviewed mainly based on our findings. Glucocorticoids (GC) exhibit diverse effects on GH secretion depending upon experimental conditions [16] . In vitro, GC enhance basal and GRH-induced GH release from cultured pituitary cells [17] [18] [19] .
GC also appear to elicit both transcriptional and posttranscriptional influences on the GH gene [20] [21] [22] [23] [24] . These genomic actions by GC on the GH gene might be involved in the GC-induced increase in basal GH secretion. On the other hand, it has previously been reported that dexamethasone (Dex) On the other hand, marked hyperglycemia induced by multiple injections of high doses of glucose partially inhibited GH surges in conscious rats (Fig. 1) . Taken together, it is assumed that acute and severe changes in blood glucose levels inhibit spontaneous GH secretion in the rat.
Effects of hypo-and hyperglycemia on hypothalamic GRH and SRIF mRNA levels (Fig. 3) , suggesting that central glucopenia stimulates hypothalamic SRIF secretion. Our results indicate that acute changes in blood glucose levels stimulate hypothalamic SRIF gene expression in the rat. Hypothalamic GRH mRNA levels are stimulated only when exposed to severe hyperglycemia.
In vitro studies [13, 14] have indicated that glucopenia stimulates both GRH and SRIF secretion from hypothalamic fragments.
We did not observe any significant increase in hypothalamic SRIF mRNA levels in vitro in rat hypothalamic fragments exposed to low glucose (Sato M, unpublished data). Although changes in mRNA levels are not always in accordance with changes in peptide release, in vitro observations so far reported may not reproduce in vivo events. were greatly increased 4 days after STZ injection and the severe hyperglycemia persisted for 14 days. Spontaneous GH secretion was gradually impaired in accordance with the persistence of hyperglycemia (Fig. 4) . Hypothalamic GRH mRNA levels were decreased 4 days after STZ injection in diabetic mice with only partially inhibitied GH secretion (Fig. 5 ). The decrease in hypothalamic GRH mRNA levels persisted for up to 14 days. In contrast, hypothalamic SRIF mRNA levels were not altered in any of the diabetic mice. These results indicate that chronic hyperglycemia primarily impairs hypothalamic GRH gene expression. The impairment of GRH synthesis seems crucial to suppression of GH secretion under diabetic conditions. Similarly in rats, hypothalamic GRH mRNA levels have been reported to be decreased during chronic diabetes [46] . Expression of pituitary GRH receptor mRNA and its quantification GRH receptor cDNA was originally cloned by Mayo in the man and rat [48] . As with other G- showed that at least 6 h was required to obtain a significant increase in GRH receptor mRNA levels (Fig. 7) . A glucocorticoids (GC) receptor-specific antagonist, RU 38486, significantly blocked the Dex-induced increase in GRH receptor mRNA levels (Fig. 7) . These results indicate that Dex increases GRH receptor mRNA levels through GC receptors located in the rat somatotropes 
Effects of insulin-induced hypoglycemia on hypothalamic c fos expression

